- Home
- DCH vs IMTX Comparison
DCH vs IMTX Comparison
Compare DCH & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$5.80
HOLD
Current Price
$11.44
Company Overview
Basic Information| Metric | DCH | IMTX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | Germany |
| Employees | 18000 | 407 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DCH | IMTX |
|---|---|---|
| Price | $5.80 | $11.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $10.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 3.2M | 287.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.65 | N/A |
| Revenue Next Year | $4.20 | $25.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.07 | $4.06 |
| 52 Week High | $8.75 | $12.41 |
Technical Indicators
Market Signals| Indicator | DCH | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 60.78 |
| Support Level | $5.39 | $9.61 |
| Resistance Level | $6.30 | $12.41 |
| Average True Range (ATR) | 0.23 | 0.47 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 50.00 | 85.25 |
Price Performance
Historical Comparison DCH
IMTX
About DCH Dauch Corporation Common Stock
Dauch Corp is a world-wide Tier 1 Automotive Supplier, Dauch designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.